RxDoctor Payments Data

Lori Wagner, APRN

Adult Health · Lexington, KYNPI 1710972260

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.3% of the total across 54 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by AbbVie at 48.3% of the total. Reporting peaked in 2022 at $593 and has fallen 78.1% since, to $130 in 2025.

$1,907in general payments, 2019–2025

Across 54 payments — averaging $35.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$922
  • Idorsia Pharmaceuticals US Inc$315
  • Amgen$141
  • Ultragenyx Pharmaceutical Inc.$125
  • Gilead$120
  • Orexo US, Inc.$70
  • plus $215 from 7 others

What the payments were for

  • Food & beverage$1,87598%
  • Education$322%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,907 in reported general payments places this provider in the 75th percentile of 170 adult health providers in Kentucky.

See all adult health providers in Kentucky

Medicare billing

Part B allowed, 2024
$8,341
Medicare patients
27
Services billed
120

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl53$11,635
Aimovig AutoinjectorErenumab-Aooe12$9,154
Armour ThyroidThyroid,pork19$1,755
Liothyronine Sodium27$1,063
Testosterone Cypionate17$793
ProgesteroneProgesterone, Micronized13$636
Levothyroxine Sodium30$348
Buspirone Hcl11$238
Topiramate12$212
Anastrozole15$111
Hydroxyzine Hcl12$68
Metformin Hcl20$40
Amlodipine Besylate16$30
Trazodone Hcl13$27
Lisinopril15$23

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieArmour Thyroid$922$1,75519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 170 adult health providers in Kentucky.

Other adult health in Lexington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →